Revolutionizing Precision Therapy: Tagworks Pharmaceuticals Secures $60 Million in Series A Funding Round

Tagworks Pharmaceuticals, a trailblazer in the development of precision therapies, has recently secured $60 million in funding to advance its innovative drug development initiatives. Known for its revolutionary Click-to-Release technology, Tagworks is dedicated to establishing a new standard of care for patients grappling with severe diseases, particularly cancer. The substantial investment will primarily support the development of their promising pipeline of click-cleavable therapies. Among these, the lead program TGW101 stands out, as it is an antibody-drug conjugate (ADC) targeting TAG72, a pan-carcinoma target that has historically been challenging for existing ADCs to effectively address. This milestone funding marks a significant step forward for Tagworks, providing the resources necessary to move its clinical programs towards fruition. The unique Click-to-Release approach facilitates on-target activation of ADCs and immunomodulators, while allowing for off-target deactivation of radioimmunotherapies, thereby enhancing their therapeutic index. This strategic infusion of capital comes at a pivotal moment in the company’s trajectory, as it seeks to revolutionize cancer treatment and ultimately improve patients’ lives. With this funding, Tagworks aims to accelerate the development and clinical trials of TGW101, as well as expand its research on additional therapies that harness the full potential of its proprietary platform.